{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:40:02Z","timestamp":1748871602201,"version":"3.41.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40487-025-00336-4","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T13:30:11Z","timestamp":1744551011000},"page":"409-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding Patients\u2019 Experiences in Newly Diagnosed Adult B\u00a0Cell Acute Lymphoblastic Leukemia: Qualitative Interviews to Develop a Patient-Centric Conceptual Model"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-4479","authenticated-orcid":false,"given":"Michael","family":"Chladek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Virginia","family":"Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-7721","authenticated-orcid":false,"given":"Maria","family":"Sae-Hau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Buenfil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3467-9932","authenticated-orcid":false,"given":"James","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-4630","authenticated-orcid":false,"given":"Faraz","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Despiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"key":"336_CR1","unstructured":"National Cancer Institute. PDQ\u00ae Adult Treatment Editorial Board. PDQ Acute Lymphoblastic Leukemia Treatment. Bethesda, MD: National Cancer Institute.  [cited 2025 Mar 23]. https:\/\/www.cancer.gov\/types\/leukemia\/hp\/adult-all-treatment-pdq2024."},{"issue":"1","key":"336_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"336_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.","journal-title":"Blood Cancer J"},{"issue":"17","key":"336_CR4","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/jcm10173792","volume":"10","author":"I Iacobucci","year":"2021","unstructured":"Iacobucci I, Kimura S, Mullighan CG. Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. J Clin Med. 2021;10(17):3792.","journal-title":"J Clin Med"},{"issue":"1","key":"336_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","volume":"2016","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):573\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"19","key":"336_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1903\u201330.","journal-title":"Blood"},{"issue":"1","key":"336_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/hematology.2021000226","volume":"2021","author":"MR Luskin","year":"2021","unstructured":"Luskin MR. Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy? Hematology Am Soc Hematol Educ Program. 2021;2021(1):7\u201314.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"13","key":"336_CR8","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/cancers15133346","volume":"15","author":"A Aureli","year":"2023","unstructured":"Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G. Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond. Cancers (Basel). 2023;15(13):3346.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"336_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ajh.26156","volume":"96","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Jabbour E, Short NJ, et al. Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980\u20132017. Am J Hematol. 2021;96(6):650\u20138.","journal-title":"Am J Hematol"},{"issue":"24","key":"336_CR10","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","volume":"36","author":"F Huguet","year":"2018","unstructured":"Huguet F, Chevret S, Leguay T, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol. 2018;36(24):2514\u201323.","journal-title":"J Clin Oncol"},{"issue":"1","key":"336_CR11","doi-asserted-by":"publisher","first-page":"Ijh02","DOI":"10.2217\/ijh-2017-0023","volume":"7","author":"Y Sawalha","year":"2018","unstructured":"Sawalha Y, Advani AS. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol. 2018;7(1):Ijh02.","journal-title":"Int J Hematol Oncol"},{"issue":"Suppl 1","key":"336_CR12","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1182\/blood-2019-130160","volume":"134","author":"I Tanasi","year":"2019","unstructured":"Tanasi I, Tagliaferri V, Tecchio C, et al. Comorbidities reduce response to induction treatment and survival in adults with philadelphia-negative acute lymphoblastic leukemia. Blood. 2019;134(Suppl 1):2587.","journal-title":"Blood"},{"key":"336_CR13","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1182\/blood-2019-121904","volume":"134","author":"A Rozental","year":"2019","unstructured":"Rozental A, Shimony S, Raanani P, Wolach O. Analysis of elderly patients (\u226570\u00a0years old) with acute leukemia in the era of targeted therapy. Blood. 2019;134:5100.","journal-title":"Blood"},{"key":"336_CR14","doi-asserted-by":"publisher","DOI":"10.2196\/39852","volume":"9","author":"R Crawford","year":"2023","unstructured":"Crawford R, Sikirica S, Morrison R, et al. The patient experience of acute lymphoblastic leukemia and its treatment: social media review. JMIR Cancer. 2023;9:e39852.","journal-title":"JMIR Cancer"},{"issue":"11","key":"336_CR15","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1080\/13696998.2016.1192549","volume":"19","author":"H Dombret","year":"2016","unstructured":"Dombret H, Thomas X, Chevallier P, et al. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. J Med Econ. 2016;19(11):1034\u20139.","journal-title":"J Med Econ"},{"key":"336_CR16","unstructured":"US Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making 2024. [cited 2025 Mar 23]. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical."},{"key":"336_CR17","first-page":"9","volume":"14","author":"C Donatti","year":"2008","unstructured":"Donatti C, Wild D, Hareendran A. The use of conceptual models, conceptual frameworks, and endpoint models to support label claims of treatment benefit using patient reported outcomes. ISPOR Connections. 2008;14:9\u20131218.","journal-title":"ISPOR Connections"},{"issue":"1","key":"336_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"4","key":"336_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27(4):591\u2013608.","journal-title":"Qual Health Res"},{"issue":"7","key":"336_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342.","journal-title":"Value Health"},{"key":"336_CR21","unstructured":"US Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Published online 2009. [cited 2025 Mar 23]. https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"336_CR22","unstructured":"US Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. June 2020. [cited 2025 Mar 23]. https:\/\/www.fda.gov\/media\/139088\/download"},{"issue":"7","key":"336_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.leukres.2013.02.009","volume":"37","author":"C Zimmermann","year":"2013","unstructured":"Zimmermann C, Yuen D, Mischitelle A, et al. Symptom burden and supportive care in patients with acute leukemia. Leuk Res. 2013;37(7):731\u20136.","journal-title":"Leuk Res"},{"key":"336_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejon.2019.05.005","volume":"41","author":"KH N\u00f8rskov","year":"2019","unstructured":"N\u00f8rskov KH, Overgaard D, Lomborg K, Kjeldsen L, Jarden M. Patients\u2019 experiences and social support needs following the diagnosis and initial treatment of acute leukemia - a qualitative study. Eur J Oncol Nurs. 2019;41:49\u201355.","journal-title":"Eur J Oncol Nurs"},{"issue":"12","key":"336_CR25","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.leukres.2013.09.018","volume":"37","author":"E Liew","year":"2013","unstructured":"Liew E, Thyagu S, Atenafu EG, Alibhai SMH, Brandwein JM. Quality of life following completion of treatment for adult acute lymphoblastic leukemia with a pediatric-based protocol. Leuk Res. 2013;37(12):1632\u20135.","journal-title":"Leuk Res"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00336-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:13:16Z","timestamp":1748869996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00336-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00336-4","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2025,4,13]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors Ana Buenfil, Michael Chladek, and James Turnbull are employees of IQVIA, which was contracted by Amgen to conduct the study, and James Turnbull has stock ownership with IQVIA. Authors Nicolas Despiegel, Faraz Zaman, and Jessie Wang are employees of Amgen. Maria Virginia Meza is a contract worker for Amgen. Author Maria Sae-Hau is an employee of The Leukemia & Lymphoma Society, which was contracted by Amgen to participate in conducting the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This interview study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice and applicable regulatory requirements. The protocol, informed consent form, and all other recruitment, interview, and patient-facing materials received approval from the WIRB Copernicus Group (WCG) institutional review board (study number 1324824). All participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors would like to thank all the patients who participated in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Participants"}}]}}